贝伐珠单抗治疗非小细胞肺癌的相关不良反应及处理原则

被引：47

作者：

程刚 ^{[1
]}

张力 ^{[2
]}

机构：

[1] 卫生部北京医院肿瘤内科

[2] 中山大学肿瘤防治中心

来源：

中国肺癌杂志 | 2010年 / 13卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

<正>一个世纪以前,研究者发现肿瘤的生长伴随着血管化程度而增加。随着研究的深入,人们认识到血管生成是肿瘤发展的关键步骤,并提出了抑制血管生成以治疗肿瘤的新策略[1,2]。血管内皮生长因子

引用

页码：563 / 567

页数：5

共 5 条

[1]

Biological mechanisms of bevacizumab-associated adverse events [J].

Higa, Gerald M. ;

Abraham, Jame .

EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) :999-1007

[2]

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis [J].

Hapani, Sanjaykumar ;

Chu, David ;

Wu, Shenhong .

LANCET ONCOLOGY, 2009, 10 (06) :559-568

[3]

9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390).[J].E. Dansin;C.M. Tsai;N. Pavlakis;J. Laskin;F. Griesinger;P. Garrido;L. Crino;Y.L. Wu;G.L. Jiang;N. Thatcher.EJC Supplements.2009, 2

[4]

9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study.[J].C. Tsai;F. Griesinger;J. Laskin;L. Crinò;N. Pavlakis;E. Dansin;N. Thatcher;Y.D. Ko;J. Metzger;P. Garrido.EJC Supplements.2009, 2

[5]

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis [J].

Zhu, Xiaolei ;

Wu, Shenhong ;

Dahut, William L. ;

Parikh, Chirag R. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (02) :186-193

← 1 →